| Literature DB >> 26265155 |
Shih-Chun Candice Lung1, Chun-Hu Liu2.
Abstract
Polycyclic aromatic hydrocarbons (PAHs) and nitro-PAHs are ubiquitous in the environment. Some of them are probable carcinogens and some are source markers. This work presents an ultra-high performance liquid chromatography-atmospheric pressure photoionization-tandem mass spectrometry (UHPLC-APPI-MS/MS) method for simultaneous analysis of 20 PAHs and nine nitro-PAHs. These compounds are separated in 15 minutes in the positive mode and 11 minutes in the negative mode, one half of GC/MS analysis time. Two pairs of precursor/product ions are offered, which is essential for confirmation. This method separates and quantifies benzo[a]pyrene (the most toxic PAHs) and non-priority benzo[e]pyrene (isomers, little toxicity) to avoid overestimation of toxin levels, demonstrating its importance for health-related researches. With 0.5% 2,4-difluoroanisole in chlorobenzene as the dopant, limits of detection of PAHs except acenaphthylene and those of nitro-PAHs except 2-nitrofluoranthene are below 10 pg and 3 pg, respectively, mostly lower than or comparable to those reported using LC-related systems. The responses were linear over two orders of magnitude with fairly good accuracy and precision. Certified reference materials and real aerosol samples were analyzed to demonstrate its applicability. This fast, sensitive, and reliable method is the first UHPLC-APPI-MS/MS method capable of simultaneously analyzing 29 environmentally and toxicologically important PAHs and nitro-PAHs.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26265155 PMCID: PMC4532996 DOI: 10.1038/srep12992
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Two pairs of precursor/product ions and the optimized MS/MS parameters for (a) PAH and (b) nitro-PAHs species.
| (a) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound (abbreviation) | Q1 | Q3 | |||||||||
| NAP- | 136.3 | 108.1 | 30.8 | 120.0 | 11.6 | 42.9 | 8.8 | 134.2 | 40.7 | 8.0 | |
| ACPY | 152.2 | 126.0 | 116.8 | 134.0 | 10.6 | 45.8 | 6.1 | 150.0 | 49.1 | 7.1 | |
| ACP- | 162.2 | 160.1 | 81.5 | 159.0 | 10.3 | 36.8 | 7.8 | 158.1 | 38.0 | 7.1 | |
| ACP | 154.2 | 153.1 | 42.8 | 193.8 | 10.0 | 31.8 | 11.0 | 152.1 | 45.1 | 8.0 | |
| FLU | 165.2 | 115.1 | 70.3 | 351.9 | 11.0 | 45.5 | 9.1 | 139.1 | 46.9 | 6.2 | |
| PHEN- | 188.3 | 160.1 | 29.1 | 161.1 | 5.2 | 46.0 | 7.2 | 186.2 | 41.1 | 9.1 | |
| PHEN | 178.2 | 176.1 | 15.5 | 83.0 | 5.1 | 49.9 | 8.3 | 152.0 | 48.1 | 7.0 | |
| ANTHR | 178.2 | 176.1 | 15.5 | 83.0 | 5.1 | 49.9 | 8.3 | 152.0 | 48.1 | 7.0 | |
| FL | 202.2 | 200.0 | 22.0 | 93.8 | 5.0 | 63.5 | 10.1 | 176.1 | 58.9 | 12.9 | |
| PYR | 202.2 | 200.0 | 22.0 | 93.8 | 5.0 | 63.5 | 10.1 | 176.1 | 58.9 | 12.9 | |
| BNT | 234.3 | 232.2 | 8.1 | 59.8 | 10.0 | 56.3 | 12.0 | 202.1 | 46.3 | 10.8 | |
| CPP | 226.3 | 224.1 | 14.9 | 59.8 | 10.9 | 68.0 | 10.0 | 200.1 | 64.3 | 10.0 | |
| BAA- | 240.3 | 236.2 | 39.9 | 189.0 | 5.2 | 56.4 | 14.0 | 238.2 | 47.2 | 14.0 | |
| BAA | 228.3 | 226.1 | 25.3 | 114.9 | 10.6 | 55.6 | 15.8 | 202.1 | 52.0 | 15.0 | |
| CHRY- | 240.3 | 236.2 | 39.3 | 189.0 | 5.2 | 56.4 | 14.0 | 238.3 | 47.2 | 14.0 | |
| CHRY | 228.3 | 226.1 | 25.3 | 114.9 | 10.6 | 55.6 | 15.8 | 202.1 | 52.0 | 15.0 | |
| RET | 234.2 | 219.2 | 18.1 | 105.1 | 5.1 | 23.0 | 10.0 | 204.2 | 25.0 | 10.9 | |
| PERY- | 264.3 | 260.1 | 30.1 | 138.0 | 10.5 | 71.6 | 6.0 | 262.2 | 55.4 | 24.0 | |
| BEP | 252.3 | 250.1 | 26.3 | 124.5 | 10.8 | 60.7 | 13.0 | 226.1 | 59.1 | 10.9 | |
| BBF | 252.3 | 250.1 | 26.3 | 124.5 | 10.8 | 60.7 | 13.0 | 226.1 | 59.1 | 10.9 | |
| BKF | 252.3 | 250.1 | 26.3 | 124.5 | 10.8 | 60.7 | 13.0 | 226.1 | 59.1 | 10.9 | |
| BAP | 252.3 | 250.1 | 26.3 | 124.5 | 10.8 | 60.7 | 13.0 | 226.1 | 59.1 | 10.9 | |
| DAA | 278.3 | 276.1 | 25.0 | 89.9 | 10.6 | 61.9 | 14.1 | 250.1 | 81.8 | 18.9 | |
| BGHIP | 276.3 | 274.1 | 17.3 | 80.3 | 10.8 | 71.8 | 14.7 | 250.1 | 66.4 | 13.0 | |
| IND | 276.3 | 274.1 | 17.3 | 80.3 | 10.8 | 71.8 | 14.7 | 250.1 | 66.4 | 13.0 | |
| COR | 300.3 | 298.2 | 25.0 | 107.0 | 10.2 | 80.4 | 12.9 | — | — | — | |
| Compound | Q1 | Q3 | |||||||||
| Positive mode | |||||||||||
| 1-nitropyrene (1NP)- | 256.2 | 226.1 | 32.3 | 156.1 | 4.8 | 27.9 | 12.1 | 240.1 | 41.7 | 14.8 | |
| 4-nitropyrene (4NP) | 247.2 | 189.1 | 23.4 | 118.7 | 7.7 | 43.1 | 8.7 | 201.1 | 31.2 | 10.7 | |
| 1NP | 247.2 | 189.1 | 23.4 | 118.7 | 7.7 | 43.1 | 8.7 | 201.1 | 31.2 | 10.7 | |
| 7-nitrobenzo[ | 273.3 | 215.1 | 16.2 | 98.0 | 8.8 | 30.8 | 11.2 | 217.1 | 23.0 | 11.5 | |
| 2-nitropyrene (2NP) | 247.2 | 201.1 | 21.6 | 110.3 | 9.9 | 31.2 | 10.7 | 189.1 | 43.1 | 8.7 | |
| 6-nitrochrysene (6NCHRY) | 273.3 | 215.1 | 16.2 | 98.0 | 8.8 | 30.8 | 11.2 | 217.1 | 23.0 | 11.5 | |
| 6-nitrobenzo[ | 297.3 | 267.1 | 19.9 | 92.1 | 9.8 | 25.3 | 14.7 | 241.0 | 28.4 | 12.4 | |
| Negative mode | |||||||||||
| 2-nitrofluorene (2NFLU) | 210.2 | 180.0 | −23.4 | −100.0 | −6.3 | −26.8 | −9.5 | 164.0 | −31.0 | −8.3 | |
| MX | 282.4 | 186.1 | −12.3 | −70.3 | −8.0 | −35.1 | −10.4 | 234.2 | −30.1 | −12.6 | |
| 1NP- | 256.3 | 226.3 | −24.3 | −119.9 | −5 | −18.4 | −37.2 | — | — | — | |
| 2-nitrofluoranthene (2NFL) | 247.3 | 217.0 | −18.0 | −100.7 | −9.5 | −20.7 | −12.8 | — | — | — | |
| 3-nitrofluoranthene (3NFL) | 247.3 | 217.0 | −18.0 | −100.7 | −9.5 | −20.7 | −12.8 | — | — | — | |
Note: DP: declustering potential, FP: focusing potential, EP: entrance potential, CE: collision energy, and CXP: collision cell exit potential.
afor BNT, second pair of Q1 (219.3) and Q3 (202.1) were identified instead of second Q3 of the Q1 (234.3), the associated DP, FP, and EP are 72.1, 130.0, and 4.7, respectively.
bnot found.
creported for the first time.
dMX: musk xylene (1-tert-butyl-3,5-dimethyl-2,4,6-trinitrobenzene).
Figure 1MRM ion chromatograms of target compounds and deuterated standards with on-column injection amounts of 300pg each; retention time (RT) for positive mode
(a,b): (1) 3.03, NAP-d8; (2) 3.47, ACPY; (3) 3.94, ACPY-d10; (4) 4.04, ACP; (5) 4.17, FLU; (6) 4.45, PHEN-d10; (7) 4.58, PHEN; (8) 5.02, ANTHR; (9) 5.44, 1NP-d9; (10) 5.47, FL; (11) 5.47, 4NP; (12) 5.55, 1NP; (13) 5.82, PYR; (14) 6.14, 7NBAA; (15) 6.22, 2NP; (16) 6.32, 6NCHRY; (17) 6.44, BNT; (18) 6.77, CPP; (19) 6.75, BAA-d12; (20) 6.95, BAA; (21) 7.05, CHRY-d12; (22) 7.27, CHRY; (23) 7.27, RET; (24) 7.92, PERY-d12; (25) 7.92, BEP; (26) 7.97, 6NBAP; (27) 8.15, BBF; (28) 8.65, BKF; (29) 9.05, BAP; (30) 9.68, DAA; (31) 10.9, BGHIP; (32) 10.5, IND; (33) 13.94, COR; RT for negative mode (c): (34) 5.67, 2NFLU; (35) 7.35, MX-d15; (36) 9.30, 1NP-d9; (37) 9.93, 2NFL; (38) 10.24, 3NFL; *other MRM (m/z:152.2–>126.0) for ACP, PHEN and ANTHR, #other MRM (247.2–>201.1) for 4NP and 1NP; ##other MRM (247.2–>189.1) for 2NP; ###benzo[b]naphtho[2,3-d]thiophene, not a target analyte; +: 4NP and ++: 1NP in the negative mode.
LODs (signal to noise ratio (S/N) equal to 3, n = 3) of 20 PAHs using UHPLC-APPI-MS/MS in this work compared to those presented in previous publications with different dopant solutions and different instrumentation; dopant A: 0.5% anisole in toluene, dopant B: 0.5% DFA in bromobenzene, and dopant C: 0.5% DFA in chlorobenzene; values shown are injection amounts (pg).
| ACPY | 225 | 94 | 24 | 11 | — f | — | 33 | — | — | — | — | 160 | 105.6 | 158.4 |
| ACP | 9.1 | 5.8 | 7.5 | 13 | — | — | 19 | — | — | — | — | 150 | 60.4 | 91.6 |
| FLU | 22 | 20 | 7.9 | 16 | — | — | 7.9 | — | — | — | — | 79 | 11.7 | 6.2 |
| PHEN | 7.7 | 7.9 | 4.4 | 9 | — | — | 12 | 15 | — | — | 461 | 190 | 10.2 | 4.3 |
| ANTHR | 5.7 | 8.7 | 6 | 10 | — | 5 | 11 | 13 | — | — | 768 | 290 | 10.4 | 3.1 |
| FL | 4.8 | 8.8 | 5.6 | 8 | — | — | 8.7 | 41 | — | — | — | 120 | 9.3 | 3.4 |
| PYR | 6.8 | 8.7 | 5.5 | 8 | — | — | 10 | 7.9 | — | — | — | 170 | 8 | 10.3 |
| BNT | 3.4 | 5 | 4.3 | — | — | — | — | — | — | — | — | — | — | — |
| CPP | 0.7 | 1.6 | 0.6 | — | 7.3 | — | — | — | — | — | — | — | — | — |
| BAA | 1.4 | 4.4 | 2 | 10 | 5 | 10 | 8.7 | 4 | 166 | 8.9 | 319 | 120 | 14.8 | 5.4 |
| CHRY | 1.3 | 3.6 | 0.9 | 8 | 8.4 | — | 9.4 | 4.1 | — | — | — | 110 | 13.9 | 11.4 |
| RET | 3.3 | 14 | 7.7 | — | — | — | — | — | — | — | — | — | — | — |
| BEP | 1.7 | 1.9 | 2.6 | — | — | — | — | 10 | — | — | — | 160 | — | — |
| BBF | 0.9 | 1.6 | 3 | — | 9 | — | 8.7 | 46 | 89 | 6.3 | — | 75 | 12.9 | 2.5 |
| BKF | 0.8 | 1.8 | 2.7 | 9 | 8.4 | — | 8.1 | 16 | 34 | 11 | — | 210 | 11.9 | 2.5 |
| BAP | 1 | 2.3 | 2.9 | 11 | 6.3 | 30 | 8.6 | 10 | 67 | 2.5 | — | 230 | 12.1 | 3.3 |
| DAA | 0.8 | 0.8 | 0.7 | 39 | 9 | — | 9.3 | — | 22 | — | — | 160 | 10.3 | 1.7 |
| BGHIP | 1.3 | 1.3 | 1.6 | 27 | 9.5 | — | 14 | — | — | — | — | 190 | 14.1 | 2.8 |
| IND | 1.3 | 1.2 | 3.2 | 28 | 7.1 | — | 13 | 7.5 | — | — | — | 260 | 11.2 | 4.4 |
| COR | 2.7 | 1.7 | 3 | — | — | — | — | — | — | — | — | — | — | — |
aLOD (pg) was converted based on the conversion factor listed in reference.
bLOD (pg) was converted from the unit of ng/mL in the references with 1 μl injection.
cLOD (pg) was converted from the unit of ng/mL in the references with 10 μl injection.
dconverted from MDL with sample loop of 10 ml.
esample matrix is oyster.
fnot found.
LODs (signal to noise ratio (S/N) equal to 3, n = 3) of nine nitro-PAHs using UHPLC-APPI-MS/MS in this work compared to those presented in previous publications with different dopant solutions and different instrumentation; dopant A: 0.5% anisole in toluene, dopant B: 0.5% DFA in bromobenzene, and dopant C: 0.5% DFA in chlorobenzene; values shown are injection amounts (pg).
| 2NFLU | 0.4 | 8.6 | 0.3 | 0.15 | 0.1–0.5 | — | 70 | 5–115 | — |
| 2NFL | 14.3 | 243 | 11.3 | 0.27 | — | — | — | — | — |
| 3NFL | 1.2 | 65 | 1.1 | 0.16 | 0.1–0.5 | — | — | 5–115 | — |
| 4NP | 1.7 | 1.7 | 1.2 | — | — | — | — | 5–115 | — |
| 1NP | 1.6 | 0.7 | 0.8 | 0.17 | 0.1–0.5 | 5 | 1 | 5–115 | 4.8 |
| 7NBAA | 2.4 | 3.2 | 2.8 | 0.3 | — | — | — | 5–115 | — |
| 2NP | 0.5 | 0.3 | 0.5 | 1.8 | — | — | — | 5–115 | — |
| 6NCHRY | 3 | 0.7 | 2 | 0.09 | 0.1–0.5 | — | — | 5-115 | — |
| 6NBAP | 1.7 | 1.5 | 0.8 | 0.65 | — | — | — | 5-115 | — |
Note:
aLOD (pg) was converted from the unit of ng/mL in the references with 10 μl injection
bnot found
cLOD ranges presented in the references
The linear range, R2, accuracy and precision of (a) 20 PAHs and (b) nine nitro-PAHs using UHPLC-APPI-MS/MS with two different dopant solutions; accuracy and precision with dopants (n = 7) are presented at two concentration levels; accuracy: percentages of the obtained concentrations over the expected concentrations; precision: values in parenthesis are percent coefficient of variation (%CV) of the repeated injections.
| Compound | ||||||||
|---|---|---|---|---|---|---|---|---|
| ACPY | 50–500 | 0.9978 | 98.8 | 96.1(6.1) | 20–500 | 0.9966 | 96.7 | 94.1(4.3) |
| ACP | 5–200 | 0.9998 | 98.0(3.6) | 103.2(2.9) | 5–200 | 0.9996 | 94.6(7.8) | 94.8(4.1) |
| FLU | 20–500 | 0.9954 | 103 | 100.8(4.6) | 10–500 | 0.9968 | 101(9.5) | 95.4(5.4) |
| PHEN | 2–500 | 0.997 | 101(6.0) | 97.1(3.8) | 5–500 | 0.9988 | 102(9.0) | 94.6(4.7) |
| ANTHR | 2–500 | 0.9976 | 101(5.1) | 99.4(3.3) | 5–500 | 0.998 | 96.8(5.1) | 93.7(3.3) |
| FL | 2–200 | 0.9978 | 107(4.1) | 103.2(3.1) | 5–500 | 0.9958 | 94.5(6.6) | 98.8(2.8) |
| PYR | 2–200 | 0.9994 | 105(3.8) | 103.8(2.3) | 5–500 | 0.9964 | 95.0(5.5) | 94.4(3.7) |
| BNT | 2–500 | 0.9982 | 98.2(7.4) | 107.4(2.7) | 5–100 | 0.9992 | 108(5.9) | 103 |
| CPP | 2–500 | 0.9996 | 98.6(6.5) | 105(3.8) | 2–200 | 0.9998 | 93.1(5.8) | 97.5(2.2) |
| BAA | 2–500 | 0.9996 | 99.9(7.6) | 104.1(3) | 2–200 | 0.9984 | 98.4(5.8) | 102(3.9) |
| CHRY | 2–500 | 0.9994 | 98.9(5.3) | 103.9(2.5) | 2–200 | 0.9994 | 97.4(7.3) | 102(4.6) |
| RET | 2–200 | 0.9974 | 94.9(5.4) | 99.8(3.8) | 10–500 | 0.9978 | 93.5(8.3) | 94.9(2.7) |
| BEP | 2–500 | 0.9968 | 95.2(4.5) | 106(2.6) | 2–200 | 0.9998 | 99.9(5.7) | 104(4.5) |
| BBF | 2–500 | 0.9958 | 100(6.8) | 100.5(1.8) | 2–200 | 0.9996 | 105(6.2) | 103(4.5) |
| BKF | 2–500 | 0.9986 | 96.9(5.6) | 104.8(3.1) | 2–200 | 0.9992 | 92.0(5.2) | 104(4) |
| BAP | 2–500 | 0.998 | 98.4(3.8) | 97.7(4.2) | 2–200 | 1.00 | 98.4(7.2) | 93.8(6.2) |
| DAA | 2–500 | 0.9972 | 106(5.0) | 102.2(2.2) | 2–200 | 0.998 | 94.7(3.8) | 94.6(3.9) |
| BGHIP | 2–500 | 0.9988 | 101(3.9) | 100.4(2.5) | 2–200 | 0.998 | 94.1(3.6) | 93.1(6.4) |
| IND | 2–500 | 0.9994 | 99.1(4.9) | 103.4(3.2) | 2–200 | 0.9998 | 92.6(8.9) | 97.8(6.2) |
| COR | 2–500 | 0.9974 | 98.9(4.4) | 107.5(3.4) | 2–200 | 0.9998 | 92.1(4.1) | 103(6.7) |
| (b) | ||||||||
| 2NFLU | 1–200 | 0.9988 | 98.8(3.7) | 97.8(2.1) | 1–200 | 0.9998 | 98.5(1.9) | 104(2.5) |
| 2NFL | 5–200 | 0.9974 | 102(7.6) | 99.4(4.1) | 5–200 | 0.9994 | 99.9(6.6) | 99.4(1.9) |
| 3NFL | 1–200 | 0.9985 | 99.1(3.4) | 96.4(4.4) | 1–200 | 1.00 | 97.2(3.9) | 106(5.5) |
| 4NP | 1–200 | 0.9988 | 109(5.4) | 98.2(3.5) | 1–200 | 0.9952 | 94.6(3.7) | 104(7.5) |
| 1NP | 1–200 | 0.995 | 102(6.5) | 102.0(5.5) | 1–200 | 0.9996 | 96.0(2.3) | 102(6.7) |
| 7NBAA | 1–200 | 0.9992 | 92.1(3.4) | 104.0(2.7) | 1-200 | 0.997 | 96.2(8.2) | 98.2(3.0) |
| 2NP | 1–200 | 0.998 | 97.6(4.5) | 99.5(3.1) | 1-200 | 0.9984 | 94.9(6.6) | 96.1(4.2) |
| 6NCHRY | 1–200 | 0.9994 | 95.6(5.7) | 99.1(4.7) | 1-200 | 0.9994 | 95.4(6.0) | 94.0(3.9) |
a50 ng/mL.
b20 ng/ml.
c100 ng/ml.
The analyzed results of NIST 1649B (n = 7) and the percentages of detectable (above the LODs) PAHs and nitro-PAHs levels in real samples (n = 58).
| % difference | % detectable in real samples | |||
|---|---|---|---|---|
| ACPY | 0.198(0.029) | 0.184(0.026) | 7.6 | 0% |
| ACP | 0.197(0.027) | 0.192(0.036) | 2.4 | 0% |
| FLU | 0.209(0.036) | 0.222(0.016) | 5.8 | 0% |
| PHEN | 3.91(0.329) | 3.94(0.047) | 0.78 | 100% |
| ANTHR | 0.41(0.059) | 0.403(0.002) | 1.8 | 74% |
| FL | 6.14(0.858) | 6.14(0.12) | 0.02 | 100% |
| PYR | 4.76(0.39) | 4.78(0.029) | 0.53 | 100% |
| BNT | − | − | − | 26% |
| CPP | 0.255(0.027) | 0.235(0.06) | 8.4 | 100% |
| BAA | 2.04(0.192) | 2.09(0.048) | 2.5 | 100% |
| CHRY | 2.96(0.28) | 3.01(0.044) | 1.5 | 100% |
| RET | 0.204(0.039) | 0.226(0.014) | 9.6 | 100% |
| BEP | 2.94(0.207) | 2.97(0.043) | 1.1 | 100% |
| BBF | 6.24(0.791) | 5.99(0.2) | 4.2 | 100% |
| BKF | 1.8(0.091) | 1.75(0.083) | 3.2 | 100% |
| BAP | 2.55(0.315) | 2.47(0.17) | 3.1 | 100% |
| DAA | 0.259(0.036) | 0.29(0.028) | 10.7 | 83% |
| BGHIP | 3.97(0.411) | 3.94(0.052) | 0.76 | 100% |
| IND | 2.92(0.397) | 2.96(0.017) | 1.2 | 100% |
| COR | 2.73(0.222) | 2.83(0.46) | 3.7 | 98% |
| (b) | (mg/kg) | (mg/kg) | ||
| 2NFLU | − | − | − | 0% |
| 2NFL | 308(15) | 311(5) | 1.1 | 0% |
| 3NFL | 4.4(0.3) | 4.6(0.1) | 5.4 | 0% |
| 4NP | 5.2(0.5) | 5.5(0.1) | 6.1 | 28% |
| 1NP | 71.1(2.9) | 71.8(1.3) | 0.98 | 19% |
| 7NBAA | 24(2.2) | 24.2(0.7) | 0.88 | 81% |
| 2NP | 11.5(0.6) | 10.8(0.3) | 6.7 | 90% |
| 6NCHRY | 4.1(0.6) | 3.8(0.1) | 7.3 | 0% |
| 6NBAP | − | − | − | 59% |
anot available.
Figure 2Analyzed results for PM2.5 samples at NTU (urban) and HL (downwind mountain) sites for (a) PAHs and (b) nitro-PAHs.